Autoimmune-like drug-induced liver injury: a review and update for the clinician

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 11, 2016, Pages 1291-1301

  Stine, Jonathan G ^a   Northup, Patrick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

acute liver failure; acute liver injury; cirrhosis; Hepatology; hepatotoxicity; outcomes; portal hypertension

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; FIBRIC ACID DERIVATIVE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IPILIMUMAB; LIVER ENZYME; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER HISTOLOGY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; RELAPSE; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

EID: 84992712510     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1211110     Document Type: Review

References (102)

1. A.Reuben, D.G.Koch, W.M.Lee Drug-induced acute liver failure:results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–2076.
2. E.Bjornsson, P.Jerlstad, A.Bergqvist, et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095–1101.
3. N.Chalasani, R.J.Fontana, H.L.Bonkovsky, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–1934. 1934.e1921–e1924
4. J.G.Stine, J.H.Lewis. Drug-induced liver injury:a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011;7(7):875–890.
5. R.J.Andrade, M.I.Lucena, M.C.Fernandez, et al. Drug-induced liver injury:an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–521.
6. N.P.Chalasani, P.H.Hayashi, H.L.Bonkovsky, et al. ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966. quiz 967
7. J.G.Stine, N.Chalasani. Chronic liver injury induced by drugs:a systematic review. Liver Int. 2015;35(11):2343–2353. doi:10.1111/liv.12958. Epub 2015 Sep 27.
8. R.J.Fontana, P.H.Hayashi, J.Gu, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108. e104
9. A.J.Czaja. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–976.
10. A.Castiella, E.Zapata, M.I.Lucena, et al. Drug-induced autoimmune liver disease:a diagnostic dilemma of an increasingly reported disease. World J Hepatol. 2014;6(4):160–168.
11. H.J.Zimmerman. Hepatotoxicity:the adverse effects of drugs and other chemicals on the liver. Philadelphia:Lippincott-Williams & Wilkins; 1999.
12. Y.Shoenfeld, Y.Vilner, T.Reshef, et al. Increased presence of common systemic lupus erythematosus (SLE) anti-DNA idiotypes (16/6 Id, 32/15 Id) is induced by procainamide. J Clin Immunol. 1987;7(5):410–419.
13. E.Bjornsson, J.Talwalkar, S.Treeprasertsuk, et al. Drug-induced autoimmune hepatitis:clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–2048.•• A series of 261 patients initially diagnosed with iAIH from the Mayo Clinic, where 24 of the patients (9%) actually had Di-AIH rather than iAIH, the majority of whom were prescribed either minocycline or nitrofurantoin.
14. A.Hisamochi, M.Kage, T.Ide, et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol. 2016;51(6):597–607. doi:10.1007/s00535-015-1131-7. Epub 2015 Oct 30.• This article showcases a longer mean latency period for DI-AIH when compared to iDILI.
15. J.G.Stine, J.H.Lewis. Current and future directions in the treatment and prevention of drug-induced liver injury:a systematic review. Expert Rev Gastroenterol Hepatol. 2016;10(4):517–536. doi:10.1586/17474124.2016.1127756. Epub 2015 Dec 25.
16. J.G.Stine, N.Intagliata, N.L.Shah, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60(4):1031–1035. Epub 12014 Nov 10626. doi:10.1007/s10620-10014-13422-x.
17. V.K.Agarwal, J.G.McHutchison, J.H.Hoofnagle. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8(5):463–470.• This article provides a list of specific elements required to evaluate potential DILI cases to aid as a clinical guide for complete DILI reporting.
18. G.P.Aithal, P.B.Watkins, R.J.Andrade, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815.
19. Z.X.Liu, N.Kaplowitz. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755–774.
20. J.H.Hoofnagle. Drug-induced liver injury network (DILIN). Hepatology. 2004;40(4):773.
21. J.H.Hoofnagle, J.Serrano, J.E.Knoben, et al. LiverTox:a website on drug-induced liver injury. Hepatology. 2013;57(3):873–874.•• A database that provides the clinician with the most up-to-date and readily accessible complete source assured of both diagnostic criteria and clinical features of DILI, an invaluable resource to the clinician in the setting of any suspected hepatotoxicity.
22. J.H.Hoofnagle. [cited 2016 Apr20]. Available from:http://livertox.nih.gov/Phenotypes_auto.html.
23. J.C.Homberg, C.Andre, N.Abuaf. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol. 1984;55(3):561–570.
24. P.H.Beaune, S.Lecoeur, M.Bourdi, et al. Anti-cytochrome P450 autoantibodies in drug-induced disease. Eur J Haematol Suppl. 1996;60:89–92.
25. S.Lecoeur, C.Andre, P.H.Beaune. Tienilic acid-induced autoimmune hepatitis:anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol. 1996;50(2):326–333.
26. M.Bourdi, J.C.Gautier, J.Mircheva, et al. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis:specificity of autoantibodies and inductive capacity of the drug. Mol Pharmacol. 1992;42(2):280–285.
27. S.Ravi, M.Shoreibah, E.Raff, et al. Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease. Dig Dis Sci. 2015;60(12):3788–3793.
28. K.Tsuneyama, H.Baba, K.Kikuchi, et al. Autoimmune features in metabolic liver disease:a single-center experience and review of the literature. Clin Rev Allergy Immunol. 2013;45(1):143–148.
29. R.Vuppalanchi, R.J.Gould, L.A.Wilson, et al. Clinical significance of serum autoantibodies in patients with NAFLD:results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int. 2012;6(1):379–385.• Autoantibodies are common in NASH but do not exert any downstream clinical consequences.
30. A.Suzuki, E.M.Brunt, D.E.Kleiner, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931–939.
31. M.P.Manns, A.J.Czaja, J.D.Gorham, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–2213. doi:10.1002/hep.23584.•• The International Autoimmune Hepatitis Group (IAHG) has well-defined histologic standards for iAIH which have been applied to diagnose DI-AIH.
32. U.B.Kuzu, E.Oztas, N.Turhan, et al. Clinical and histological features of idiosyncratic liver injury:dilemma in diagnosis of autoimmune hepatitis. Hepatol Res. 2016;46(4):277–291. doi:10.1111/hepr.12530. Epub 2015 May 21.
33. European Association for the Study of the Liver. EASL clinical practice guidelines:autoimmune hepatitis. J Hepatol. 2015; 63(4):971–1004.•• Suggested algorithm for diagnosing and treating DI-AIH.
34. N.Chalasani, E.Bjornsson. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–2259.
35. J.N.Pande, S.P.Singh, G.C.Khilnani, et al. Risk factors for hepatotoxicity from antituberculosis drugs:a case-control study. Thorax. 1996;51(2):132–136.
36. E.Bjornsson, L.Davidsdottir. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50(3):511–517.
37. J.G.Stine, P.Sateesh, J.H.Lewis. Drug-induced liver injury in the elderly. Curr Gastroenterol Rep. 2013;15(1):299.
38. M.M.Cotreau, L.L.Von Moltke, D.J.Greenblatt. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33–60.
39. R.Voskuhl. Sex differences in autoimmune diseases. Biol Sex Differ. 2011;2(1):1.
40. J.Lindberg, A.Lindholm, S.Iwarson. Genetic factors in the development of chronic active hepatitis. Lancet. 1977;1(8002):67–68.
41. M.I.Lucena, N.Kaplowitz, H.Hallal, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry:the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55(4):820–827. Epub 2011 Feb 1019. 10.1016/j.jhep.2010.12.041.•• The majority of recurrent DILI cases have features of autoimmunity.
42. T.Podymow, P.August. Hypertension in pregnancy. Adv Chronic Kidney Dis. 2007;14(2):178–190.
43. G.B.Goldstein, K.C.Lam, S.P.Mistilis. Drug-induced active chronic hepatitis. Am J Dig Dis. 1973;18(3):177–184.
44. P.J.Toghill, P.G.Smith, P.Benton, et al. Methyldopa liver damage. Br Med J. 1974;3(5930):545–548.
45. E.A.Sotaniemi, O.T.Hokkanen, J.T.Ahokas, et al. Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage. Eur J Clin Pharmacol. 1977;12(6):429–435.
46. A.J.Arranto, E.A.Sotaniemi. Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short- and long-term exposure. Scand J Gastroenterol. 1981;16(7):853–863.
47. M.Beaugrand, C.Gavillon, J.P.Ferrier. [High levels of endoplasmic reticulum antibody titer in a case of alpha-methyldopa-induced chronic active hepatitis (author’s transl)]. Gastroenterol Clin Biol. 1980;4(3):219–221.
48. W.M.Lee, W.T.Denton. Chronic hepatitis and indolent cirrhosis due to methyldopa:the bottom of the iceberg? J S C Med Assoc. 1989;85(2):75–79.
49. A.J.Arranto, E.A.Sotaniemi. Histologic follow-up of alpha-methyldopa-induced liver injury. Scand J Gastroenterol. 1981;16(7):865–872.
50. W.C.Roberts. Safety of fenofibrate – US and worldwide experience. Cardiology. 1989;76(3):169–179.
51. J.Dumortier, R.Slim, M.Chevallier, et al. [Acute severe fibrosing hepatitis associated with ciprofibrate treatment]. Gastroenterol Clin Biol. 1999;23(12):1399–1400.
52. P.Chatrenet, C.Regimbeau, J.P.Ramain, et al. [Chronic active cirrhogenic hepatitis induced by fenofibrate]. Gastroenterol Clin Biol. 1993;17(8–9):612–613.
53. P.H.Bernard, H.Lamouliatte, B.Le Bail, et al. [Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate]. Gastroenterol Clin Biol. 1994;18(11):1048–1049.
54. J.L.Parra, K.R.Reddy. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7(2):415–433.
55. P.Couzigou, P.Boutillier, C.Boisseau, et al. [Drug-induced hepatitis due to fenofibrate]. Therapie. 1980;35(3):403.
56. FDA Drug Safety Communication:Important safety label changes to cholesterol-lowering statin drugs [Internet; cited 2016 Mar 21]. Available from:www.fda.gov/Drugs/DrugSafety/ucm293101.htm
57. J.H.Lewis. Clinical perspective:statins and the liver – harmful or helpful? Dig Dis Sci. 2012;57(7):1754–1763.
58. T.Funatsu, H.Kakuta, T.Takasu, et al. Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model. Metabolism. 2003;52(5):609–615.
59. N.Pelli, M.Setti, P.Ceppa, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15(8):921–924.
60. V.Alla, J.Abraham, J.Siddiqui, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006;40(8):757–761.
61. M.W.Russo, J.H.Hoofnagle, J.Gu, et al. Spectrum of statin hepatotoxicity:experience of the drug-induced liver injury network. Hepatology. 2014;60(2):679–686.
62. C.van Heyningen. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem. 2005;42(Pt 5):402–404.
63. L.M.Wolters, H.R.Van Buuren. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2005;17(5):589–590.
64. R.Kasliwal, L.V.Wilton, V.Cornelius, et al. Safety profile of rosuvastatin:results of a prescription-event monitoring study of 11,680 patients. Drug Safety. 2007;30(2):157–170.
65. Z.Punthakee, L.J.Scully, M.M.Guindi, et al. Liver fibrosis attributed to lipid lowering medications:two cases. J Intern Med. 2001;250(3):249–254.
66. R.Mansilla-Tinoco, S.J.Harland, P.J.Ryan, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J (Clin Res Ed). 1982;284(6320):936–939.
67. C.Belloc, A.Gauffre, C.Andre, et al. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. Pharmacogenetics. 1997;7(3):181–186.
68. F.S.Hodi, S.J.O’Day, D.F.McDermott, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
69. K.C.Kahler, A.Hauschild. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011;9(4):277–286.
70. R.Cheng, A.Cooper, J.Kench, et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol. 2015;30(4):657–666.
71. D.E.Kleiner, D.Berman. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57(8):2233–2240.
72. J.S.Weber, K.C.Kahler, A.Hauschild. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–2697.
73. T.Ahmed, R.Pandey, B.Shah, et al. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. 2015;2015:pii:bcr2014208102. doi:10.1136/bcr-2014-208102.
74. K.D.Chmiel, D.Suan, C.Liddle, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29(9):e237–240.
75. S.R.Knowles, L.Shapiro, N.H.Shear. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol. 1996;132(8):934–939.
76. R.Gleckman, S.Alvarez, D.W.Joubert. Drug therapy reviews:nitrofurantoin. Am J Hosp Pharm. 1979;36(3):342–351.
77. J.R.Sharp, K.G.Ishak, H.J.Zimmerman. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med. 1980;92(1):14–19.
78. G.Amit, P.Cohen, Z.Ackerman. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J. 2002;4(3):184–186.
79. P.J.Sippel, W.A.Agger. Nitrofurantoin-induced granulomatous hepatitis. Urology. 1981;18(2):177–178.
80. J.G.Stine, J.H.Lewis. Hepatotoxicity of antibiotics:a review and update for the clinician. Clin Liver Dis. 2013;17(4):609–642, ix.
81. H.Strohscheer, H.H.Wegener. [Nitrofurantoin-induced granulomatous hepatitis]. MMW Munch Med Wochenschr. 1977;119(47):1535–1536.
82. O.Selroos, J.Edgren. Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin. Report of three cases. Acta Med Scand. 1975;197(1–2):125–129.
83. S.Iwarson, J.Lindberg, P.Lundin. Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases. Scand J Gastroenterol. 1979;14(4):497–502.
84. H.Klemola, O.Penttila, L.Runeberg, et al. Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol. 1975;10(5):501–505.
85. B.Fagrell, I.Strandberg, B.Wengle. A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report. Acta Med Scand. 1976;199(3):237–239.
86. J.G.Stine, O.S.Khokhar, J.Charalambopoulos, et al. Rheumatologists’ awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care & Research. 2010;62(5):704–711.
87. O.S.Khokhar, J.H.Lewis. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis. 2010;28(3):508–518.
88. T.Adar, M.Mizrahi, O.Pappo, et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44(1):e20–22.
89. S.Mancini, E.Amorotti, S.Vecchio, et al. Infliximab-related hepatitis:discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193–200.
90. Y.Poulin, G.Therien. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis:case report and literature review. J Cutan Med Surg. 2010;14(2):100–104.
91. S.Mancini, E.Amorotti, S.Vecchio, et al. Infliximab-related hepatitis:discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193–200. Epub 12010 Jan 11727. doi:10.1007/s11739-009-0342-4.
92. J.H.Lewis. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015;13(12):2173–2189.e8. doi:10.1016/j.cgh.2015.06.017. Epub 2015 Jun 23.
93. G.P.Aithal. Pharmacogenetic testing in idiosyncratic drug-induced liver injury:current role in clinical practice. Liver Int. 2015;35(7):1801–1808.
94. M.T.Hawkins, J.H.Lewis. Latest advances in predicting DILI in human subjects:focus on biomarkers. Expert Opin Drug Metab Toxicol. 2012;8(12):1521–1530.
95. J.R.Senior. New biomarkers for drug-induced liver injury:are they really better? What do they diagnose? Liver Int. 2014;34(3):325–327.
96. P.B.Watkins. Managing the risk of drug-induced liver injury. Clin Pharmacol Ther. 2013;94(6):629–631.
97. E.Phillips, S.Mallal. Successful translation of pharmacogenetics into the clinic:the abacavir example. Mol Diagn Ther. 2009;13(1):1–9.
98. A.K.Daly. Human leukocyte antigen (HLA) pharmacogenomic tests:potential and pitfalls. Curr Drug Metab. 2014;15(2):196–201.
99. T.J.Urban, A.K.Daly, G.P.Aithal. Genetic basis of drug-induced liver injury:present and future. Semin Liver Dis. 2014;34(2):123–133.
100. X.Yang, W.F.Salminen, Q.Shi, et al. Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children. Toxicol Appl Pharmacol. 2015;284(2):180–187.
101. F.Momen-Heravi, S.Bala, T.Bukong, et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine. 2014;10(7):1517–1527.
102. L.A.Possamai, M.J.McPhail, W.Khamri, et al. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. Liver Int. 2015;35(3):764–773.